Literature DB >> 26228638

Increased morbidity during long-term follow-up of survivors of thrombotic thrombocytopenic purpura.

Shruti Chaturvedi1, Hashim Abbas2, Keith R McCrae3,4.   

Abstract

Entities:  

Mesh：

Year:  2015        PMID： 26228638      PMCID： PMC4579009          DOI： 10.1002/ajh.24138

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


× No keyword cloud information.
  6 in total

Review 1.  von Willebrand factor: an emerging target in stroke therapy.

Authors:  Simon F De Meyer; Guido Stoll; Denisa D Wagner; Christoph Kleinschnitz
Journal:  Stroke       Date:  2011-12-15       Impact factor: 7.914

2.  Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura.

Authors:  Cassandra C Deford; Jessica A Reese; Lauren H Schwartz; Jedidiah J Perdue; Johanna A Kremer Hovinga; Bernhard Lämmle; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Blood       Date:  2013-07-09       Impact factor: 22.113

3.  Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction.

Authors:  Masakazu Matsukawa; Koichi Kaikita; Kenji Soejima; Shunichiro Fuchigami; Yoshinori Nakamura; Tsuyoshi Honda; Kenichi Tsujita; Yasuhiro Nagayoshi; Sunao Kojima; Hideki Shimomura; Seigo Sugiyama; Kazuteru Fujimoto; Michihiro Yoshimura; Tomohiro Nakagaki; Hisao Ogawa
Journal:  Am J Cardiol       Date:  2007-06-12       Impact factor: 2.778

4.  Depression, post-traumatic stress disorder, and functional disability in survivors of critical illness in the BRAIN-ICU study: a longitudinal cohort study.

Authors:  James C Jackson; Pratik P Pandharipande; Timothy D Girard; Nathan E Brummel; Jennifer L Thompson; Christopher G Hughes; Brenda T Pun; Eduard E Vasilevskis; Alessandro Morandi; Ayumi K Shintani; Ramona O Hopkins; Gordon R Bernard; Robert S Dittus; E Wesley Ely
Journal:  Lancet Respir Med       Date:  2014-04-07       Impact factor: 30.700

5.  Long term outcome and sequelae in patients after acute thrombotic thrombocytopenic purpura episodes.

Authors:  T Falter; K J Alber; I Scharrer
Journal:  Hamostaseologie       Date:  2013-04-19       Impact factor: 1.778

6.  Cognitive deficits after recovery from thrombotic thrombocytopenic purpura.

Authors:  April S Kennedy; Qurana F Lewis; James G Scott; Johanna A Kremer Hovinga; Bernhard Lämmle; Deirdra R Terrell; Sara K Vesely; James N George
Journal:  Transfusion       Date:  2009-02-13       Impact factor: 3.157
  6 in total
  10 in total

1.  Atypical presentations of thrombotic thrombocytopenic purpura: a diagnostic role for ADAMTS13.

Authors:  Yosef Kalish; Amihai Rottenstreich; Deborah Rund; Sarit Hochberg-Klein
Journal:  J Thromb Thrombolysis       Date:  2016-08       Impact factor: 2.300

Review 2.  TTP: long-term outcomes following recovery.

Authors:  James N George
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

3.  Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors.

Authors:  Harshvardhan Upreti; Jamil Kasmani; Kathryn Dane; Evan M Braunstein; Michael B Streiff; Satish Shanbhag; Alison R Moliterno; C John Sperati; Rebecca F Gottesman; Robert A Brodsky; Thomas S Kickler; Shruti Chaturvedi
Journal:  Blood       Date:  2019-08-20       Impact factor: 22.113

4.  Major adverse cardiovascular events in survivors of immune-mediated thrombotic thrombocytopenic purpura.

Authors:  Max A Brodsky; Senthil Sukumar; Sruthi Selvakumar; Lisa Yanek; Sarah Hussain; Marshall A Mazepa; Evan M Braunstein; Alison R Moliterno; Thomas S Kickler; Robert A Brodsky; Spero R Cataland; Shruti Chaturvedi
Journal:  Am J Hematol       Date:  2021-09-15       Impact factor: 10.047

5.  Cost savings to hospital of rituximab use in severe autoimmune acquired thrombotic thrombocytopenic purpura.

Authors:  George Goshua; Amit Gokhale; Jeanne E Hendrickson; Christopher Tormey; Alfred Ian Lee
Journal:  Blood Adv       Date:  2020-02-11

6.  Plasmapheresis in Sepsis-induced Thrombotic Microangiopathy: A Case Series.

Authors:  Sushmita Rs Upadhya; Chakrapani Mahabala; Jayesh G Kamat; Jayakumar Jeganathan; Sushanth Kumar; Mayur V Prabhu
Journal:  Indian J Crit Care Med       Date:  2020-03

7.  Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission.

Authors:  Senthil Sukumar; Max Brodsky; Sarah Hussain; Lisa Yanek; Alison Moliterno; Robert Brodsky; Spero R Cataland; Shruti Chaturvedi
Journal:  Blood Adv       Date:  2022-02-22

Review 8.  Severe Thrombotic Thrombocytopenic Purpura (TTP) with Organ Failure in Critically Ill Patients.

Authors:  Sofiane Fodil; Lara Zafrani
Journal:  J Clin Med       Date:  2022-02-19       Impact factor: 4.241

9.  Epidemiology, treatment patterns, clinical outcomes, and disease burden among patients with immune-mediated thrombotic thrombocytopenic purpura in the United States.

Authors:  Ayoade Adeyemi; Francesca Razakariasa; Alexandra Chiorean; Rui de Passos Sousa
Journal:  Res Pract Thromb Haemost       Date:  2022-09-16

Review 10.  Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase.

Authors:  John Paul Westwood; Marie Scully
Journal:  Ther Adv Hematol       Date:  2022-07-26
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.